Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 10/2015

01-10-2015 | Original Contributions

The Effect and Predictive Score of Gastric Bypass and Sleeve Gastrectomy on Type 2 Diabetes Mellitus Patients with BMI < 30 kg/m2

Authors: Wei-Jei Lee, Abdullah Almulaifi, Keong Chong, Shu-Chun Chen, Jun Juin Tsou, Kong-Han Ser, Yi-Chih Lee, Jung-Chien Chen

Published in: Obesity Surgery | Issue 10/2015

Login to get access

Abstract

Background

Metabolic surgery is a novel therapy for mild obesity (BMI 30–35 Kg/m2) in type 2 diabetes mellitus (T2DM) patients. The ABCD score, which comprise age, BMI, C-peptide level, and duration of T2DM (years), was reported as useful in predicting the success of T2DM treatment using metabolic surgery. This study examines gastric bypass and sleeve gastrectomy as a salvage treatment for non-obese (BMI < 30 kg/m2) T2DM patients and evaluates the role of ABCD scores.

Methods

From January 2007 to July 2013, 512 (71.2 %) of 711 T2DM patients enrolled in a metabolic surgical program had at least 1-year follow-up were recruited. Clinical data and outcomes of 80 (15.6 %) patients with BMI < 30 Kg/m2 were compared with those of the other 432 (84.4 %) patients with BMI ≥ 30 Kg/m2. Complete remission was defined as HbA1c ≤ 6 %, and partial remission was defined as HbA1c < 6.5 %. A binary logistic regression was used to identify predictors of T2DM remission.

Results

Mean age of the 80 non-obese T2DM patients was 47.7 ± 9.1 years, and mean HbA1c and disease duration were 9.1 ± 1.8 % and 6.5 ± 5.1 years, respectively. Mean total body weight loss was 17.1 ± 7.4 % at 1 year, and mean BMI decreased from 26.9 ± 2.2 to 22.7 ± 2.5 kg/m2 at 1 year. Complete remission of T2DM was achieved in 25.0 % of patients, and partial remission was achieved in 23.8 %. The complete remission rate was significantly lower than the 49.5 % found in patients with BMI 30–35 and 79.0 % of patients with BMI > 35 Kg/m2. In univariate analysis, non-obese patients who had T2DM remission after surgery were heavier and had a wider waist, higher C-peptide levels, shorter disease duration, more weight loss, and higher ABCD score than those without remission. The ABCD score remained the only independent predictor of success after multivariate logistical regression analyses (P = 0.003).

Conclusions

Metabolic surgery may be useful in achieving glycemic control of selected non-obese T2DM patients. The ABCD score is a simple multidimensional grading system that can predict the success of T2DM treatment.
Literature
1.
Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311–2.CrossRefPubMed
2.
Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129–40.CrossRefPubMed
3.
Stark Casagrande S, Fradkin JE, Saydah SH, et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1998–2010. Diabetes Care. 2013;36(8):2271–9.PubMedCentralCrossRefPubMed
4.
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.CrossRefPubMed
5.
Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. NEJM. 2004;351:2683–93.CrossRefPubMed
6.
Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316–23.PubMed
7.
Lee WJ, Chong K, Ser KH, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg. 2011;146:143–8.CrossRefPubMed
8.
Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567–76.PubMedCentralCrossRefPubMed
9.
Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the diabetes surgery study randomized clinical trial. JAMA. 2013;309(21):2240–9.PubMedCentralCrossRefPubMed
10.
Liang Z, Wu Q, Chen B, et al. Effect of laparoscopic Roux-en-Y gastric bypass for type 2 diabetes mellitus with hypertension: a randomized controlled trial. Diabetes Res Clin Pract. 2013;101(1):50–6.CrossRefPubMed
11.
Wentworth J, Playfair J, Lavrie C, et al. Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomized controlled trial. Lancet Diabetes Endocrinol. 2014;2(7):545–52.CrossRefPubMed
12.
Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33(Suppl 1):S62–9.
13.
14.
Lee WJ, Hur KY, Lakadawala M, et al. Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score. Surg Obes Relat Dis. 2013;9:379–84.CrossRefPubMed
15.
Dixon J, Chung LM, Chong K, et al. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes Care. 2013;36:20–6.PubMedCentralCrossRefPubMed
16.
Dixon J, Hur KJ, Lee WJ, et al. Gastric bypass in Type 2 diabetes with BMI < 30: weight and weight loss have a major influence on outcomes. Diabet Med. 2013;30:e127–34.CrossRefPubMed
17.
Matthews DR, Hosker JP, Rudensky AS, et al. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412–9.CrossRefPubMed
18.
19.
Ser KH, Lee WJ, Lee YC, et al. Experience in laparoscopic sleeve gastrectomy for morbid obese Taiwanese: staple-line reinforcement is important for preventing leakage. Surg Endosc. 2010;16:2253–9.CrossRef
20.
Carcia-Caballero M, Valle M, Martinez-Moreno JM, et al. Resolution of diabetes mellitus and metabolic syndrome in normal weight 24–29 BMI patients with one anastomosis gastric bypass. Nutr Hops. 2012;27:623–31.
21.
Geloneze B, Gelonee SR, Chaim E, et al. Metabolic surgery for non-obese type 2 diabetes: incretin, adipocytokines, and insulin secretion/resistance changes in a 1-year interventional clinical controlled study. Ann Surg. 2012;256:72–8.CrossRefPubMed
22.
Lee WJ, Ser KH, Chong K, et al. Laparoscopic sleeve gastrectomy for diabetes treatment in non-morbidly obese patients: efficacy and change of insulin secretion. Surgery. 2010;147:664–9.CrossRefPubMed
23.
Scopinaro N, Adami GF, Papadia FS, et al. Effects of biliopancreatic diversion on type 2 diabetes in patients with BMI 25–35. Ann Surg. 2011;253:699–703.CrossRefPubMed
24.
Kim MJ, Hur KY. Short-term outcomes of laparoscopic single anastomosis gastric bypass (LSAGB) for the treatment of type 2 diabetes in lower BMI (<30 Kg/m2) patients. Obes Surg. 2014;24:1044–51.CrossRefPubMed
25.
Cummings D, Cohen RV. Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Eendocrinol. 2014;2:175–81.CrossRef
26.
27.
DeFronzo RA. Diab Care 1998; Am J Med 2009;122(6)j.
28.
Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes. 2008;57:1340–8.CrossRefPubMed
29.
Lee WJ, Chong K, Chen RC, et al. Predictors of diabetes remission after bariatric surgery in Asian. Asian J Surg. 2012;35:67–73.CrossRefPubMed
30.
Blackstone R, Bunt JC, Cortes MC, et al. Type 2 diabetes after gastric bypass: remission in five models using HbA1c, fasting blood glucose, and medication status. Surg Obes Relat Dis. 2012;8:548–55.CrossRefPubMed
31.
Still CD, Wood GC, Benotti P, et al. A probability score for preoperative prediction of type 2 diabetes remission following RYGB surgery. Lancet Diabetes Endocrinol. 2014;2:38–45.PubMedCentralCrossRefPubMed
32.
Carrison LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Sweden obese subjects. NEJM. 2012;367:2683–93.
33.
Lee WJ, Chong K, Ser KH, et al. C-peptide predicts the remission of type 2 diabetes after bariatric surgery. Obes Surg. 2012;22:293–8.CrossRefPubMed
34.
Arts EOI, Janssen J, Jassen IM, et al. Preoperative fasting plasma C-peptide level may help to predict diabetes outcome after gastric bypass surgery. Obes Surg. 2013;23:867–73.CrossRef
35.
Cohen RV, Petry TZ, Caravatto PP. Low levels of C-peptide may not be a sign of pancreatic B-cell death or apoptosis: new insight into pancreatic endocrine function and indications for metabolic surgery. Surg Obes Relat Dis. 2013;9:1022–4.CrossRefPubMed
36.
Thaler JP, Cummings DE. Minireview: hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology. 2009;150(6):2518–25.CrossRefPubMed
37.
DePaula AL, Macedo AL, Rassi N, et al. Laparoscopic treatment of metabolic syndrome in patients with type 2 diabetes mellitus. Surg Endosc. 2008;22(12):2670–8.CrossRefPubMed
38.
Ramos AC, Galvao N, de Souza YM, et al. Laparoscopic duodenal-jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI < 30 Kg/m2 (LBMI). Obes Surg. 2009;19:307–11.CrossRefPubMed
39.
Cohen R, Caravatto PP, Correa JL, et al. Glycemic control after stomach-sparing duodenal-jejunal bypass surgery in diabetic patients with low body mass index. Surg Obes Relat Dis. 2012;8:375–80.CrossRefPubMed
40.
Kim JW, Cheong JH, Hyung WJ, et al. Outcome after gastrectomy in gastric cancer patients with type 2 diabetes. World J Gastroenterol. 2012;18(1):49–54.PubMedCentralCrossRefPubMed
Metadata
Title
The Effect and Predictive Score of Gastric Bypass and Sleeve Gastrectomy on Type 2 Diabetes Mellitus Patients with BMI < 30 kg/m2
Authors
Wei-Jei Lee
Abdullah Almulaifi
Keong Chong
Shu-Chun Chen
Jun Juin Tsou
Kong-Han Ser
Yi-Chih Lee
Jung-Chien Chen
Publication date
01-10-2015
Publisher
Springer US
Published in
Obesity Surgery / Issue 10/2015
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-015-1603-0

Other articles of this Issue 10/2015

Obesity Surgery 10/2015 Go to the issue

Letter to Editor/LED Reply

Reply to a Letter to the Editor: Bariatric Surgery in Class I Obesity. A Position Statement from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)—Obesity Surgery 2014;24:487–519

Original Contributions

Formation of the Scandinavian Obesity Surgery Registry, SOReg

How I Do It

Laparoscopic Revision of an Omega Loop Gastric Bypass to Treat Afferent Loop Syndrome

Letter to the Editor

Using Ligasure™ or Harmonic Ace® in Laparoscopic Sleeve Gastrectomies? A Prospective Randomised Study

Original Contributions

Feasibility of Smartphone-Based Education Modules and Ecological Momentary Assessment/Intervention in Pre-bariatric Surgery Patients

Video Submission

Management of Type 2 Late Sleeve Leak by Laparoscopic Suturing and Conversion to Roux-en-Y Gastric Bypass: Video Report